Results 41 to 50 of about 85,538 (123)
Selection of Optimal Neoadjuvant Therapy Before Cytoreductive Nephrectomy and Its Biomarker in Renal Cell Carcinoma [PDF]
Journal of Urologic OncologyCytoreductive nephrectomy (CN) has been a pivotal consideration in the treatment of metastatic renal cell carcinoma, with its role evolving significantly in the era of immuno-oncology (IO) therapies.
Renpei Kato
doaj +1 more source
Patient Expectations in High‐Risk Abdominal Surgery for Cancer
Health Expectations, Volume 29, Issue 4, August 2026.ABSTRACT Background Despite the central role of expectations in informed consent and surgical shared decision‐making, patient expectations frequently remain unelicited or underexplored and are often assumed rather than explicitly addressed. Objective To explore how patients form expectations about high‐risk abdominal surgery for cancer and how ...
Kimberly E. Kopecky +6 more
wiley +1 more source
Drugs in ContextWe report the case of a 65-year-old woman diagnosed with metastatic chromophobe renal cell carcinoma, classified as intermediate risk according to IMDC criteria, who presented with a large left renal mass, para-aortic lymphadenopathy and bilateral ...
Laura Palumbo +4 more
doaj +1 more source
Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
, 2007 The objective of this study was to determine our institutional experience with cytoreductive nephrectomy alone or in conjunction with nephrectomy complete metastasectomy.
Paul Russo +4 more
core +1 more source
Clinical Case Reports, Volume 14, Issue 5, May 2026.ABSTRACT Colosplenic fistula is a rare complication most commonly associated with colonic lymphoma, adenocarcinoma, and Crohn's disease. In unstable and septic patients, a staged strategy consisting of initial laparoscopic source control and diversion followed by definitive multivisceral resection can balance urgent management of sepsis with adherence ...
Kanhua Yin +2 more
wiley +1 more source
IJU Case Reports, Volume 9, Issue 3, May 2026.ABSTRACT Introduction Nivolumab plus ipilimumab is a standard first‐line regimen for advanced renal cell carcinoma; however, primary tumors often respond less favorably to this combination than to immune checkpoint inhibitor–tyrosine kinase inhibitor regimens, and pathological complete response is rare.
Takuto Tsuchiya +9 more
wiley +1 more source
Med Research, Volume 2, Issue 1, Page 89-105, March 2026.Preoperative VEGFR‐TKI plus ICI therapy in advanced ccRCC normalizes tumor vasculature, enhances CD8⁺ T/B cell infiltration, and promotes TLS maturation, leading to profound tumor microenvironment remodeling. These immunologic changes improve the feasibility of 3D reconstruction‐guided robotic cytoreductive nephron‐sparing surgery, resulting in reduced
Wenhao Xu +10 more
wiley +1 more source
, 2010 2010, 1st quarter-; Description based on: 1st quarter 2010; title from PDF caption (viewed on Dec. 7, 2010).; At head of title: Ohio Deferred Compensation.; "A publication of the Ohio Deferred Compensation Board."; Harvested from the web on 5/12 ...
core +4 more sources
Cytoreductive nephrectomy for metastatic renal cell carcinoma
, 2013 Renal cell carcinoma is the most lethal urologic malignancy. Up to 30% of patients with kidney cancer have metastatic disease and 30% of those treated for local or locally advanced disease progress to metastases.
Rajendra B Nerli
core +1 more source
IJU Case Reports, Volume 9, Issue 1, January 2026.ABSTRACT Introduction Direct liver invasion by renal cell carcinoma (RCC) is rare and often precludes margin‐negative resection. Herein, we report a case where neoadjuvant treatment with avelumab plus axitinib downstaged the disease, enabling complete surgical resection. Case Presentation A 67‐year‐old woman presented with gross hematuria.
Fumihiro Ito +4 more
wiley +1 more source